GlassScriptPhysician profile
Samia Boufares
NPI 1639626351
$4,743.00
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,102 · 2022: $1,146 · 2023: $893 · 2024: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,343.42 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $752.67 | 2021-2024 | Relistor |
| Abbvie INC. | $752.57 | 2021-2024 | |
| Abbott Laboratories | $267.94 | 2021-2024 | Proclaim |
| Nevro Corp. | $214.06 | 2021-2024 | Senza |
| Collegium Pharmaceutical, INC. | $184.25 | 2021-2024 | Xtampza, Belbuca |
| Biohaven Pharmaceutical Holding Company LTD. | $176.32 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $173.46 | 2021-2024 | Ajovy |
| Pfizer INC. | $141.76 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $137.14 | 2022-2024 | |
| Amgen INC. | $133.55 | 2021-2022 | |
| Curonix LLC | $126.24 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Lilly USA, LLC | $49.04 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $47.18 | 2021 | |
| Allergan, INC. | $44.24 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $43.51 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $38.18 | 2021-2022 | |
| Vertos Medical, INC. | $23.90 | 2024 | Mild Device Kit |
| Boston Scientific Corporation | $21.75 | 2024 | Wavewriter Alpha Prime 16 |
| Supernus Pharmaceuticals, INC. | $21.52 | 2021 | |
| Ibsa Pharma INC. | $19.70 | 2022 | |
| Alfasigma USA, INC. | $15.48 | 2021 | |
| Saluda Medical Americas, INC. | $15.12 | 2023 | Evoke Scs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samia Boufares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.